Aadi Bioscience, Inc.

NasdaqCM:AADI Stock Report

Market Cap: US$41.3m

Aadi Bioscience Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Dave Lennon

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure2.2yrs
Board average tenure2.7yrs

Recent management updates

Recent updates

Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Mar 07
Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified

Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Feb 12
Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Dec 16
Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge

Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Nov 10
Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Oct 03
Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Jun 28
Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Mar 04
Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors

Oct 12

A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)

Sep 28
A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)

Aadi Bioscience: Taking mTOR Inhibition To The Next Level

Sep 21

Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Jul 06
Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?

Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes

Jun 23

What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Nov 27
What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today

Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning

Nov 25

CEO

Dave Lennon (52 yo)

less than a year

Tenure

Mr. David J. Lennon, Ph.D. also known as Dave, is the Treasurer at Alliance for Regenerative Medicine from April, 2022. He is the CEO of Satellite Bio. He serves as President and CEO & Director at Aadi Bio...


Leadership Team

NamePositionTenureCompensationOwnership
Neil Desai
Founder12.5yrsUS$3.05m8.19%
$ 3.4m
Loretta Itri
Chief Medical Officer2.5yrsUS$1.66m0.012%
$ 5.0k
David Lennon
Presidentless than a yearno datano data
Scott Giacobello
CFO, Treasurer2.4yrsUS$4.47m0.081%
$ 33.6k
Stephen Rodin
Senior VP of Legal & General Counsel2.2yrsno datano data
Raymond Steitz
Senior VP of Human Resources & Chief Human Resources Officer1.8yrsno datano data
Bryan Ball
Chief Quality Officer & Senior VP of Manufacturing Operations1.7yrsno datano data

2.2yrs

Average Tenure

53yo

Average Age

Experienced Management: AADI's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Neil Desai
Founder12.5yrsUS$3.05m8.19%
$ 3.4m
David Lennon
Presidentless than a yearno datano data
Caley Castelein
Independent Director2.7yrsUS$252.00k0.080%
$ 33.1k
Emma Reeve
Independent Director2.6yrsUS$240.00k0%
$ 0
Anupam Dalal
Independent Director2.7yrsUS$235.00k0.0046%
$ 1.9k
Karin Hehenberger
Independent Director2.7yrsUS$282.50k0%
$ 0
Richard Maroun
Independent Director7.2yrsUS$240.00k0%
$ 0
Mohammad Hirmand
Independent Director1.1yrsno datano data
Behzad Aghazadeh
Independent Director2.7yrsUS$224.50k0%
$ 0

2.7yrs

Average Tenure

52yo

Average Age

Experienced Board: AADI's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.